Ahn Dongbin, Heo Sung Jae, Lee Gil Joon, Sohn Jin Ho, Jeong Ji Yun
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-g, Daegu 41944, Republic of Korea.
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-g, Daegu 41944, Republic of Korea.
Auris Nasus Larynx. 2022 Apr;49(2):229-234. doi: 10.1016/j.anl.2021.07.011. Epub 2021 Aug 14.
This study evaluated the prevalence and characteristics of tonsillar human papillomavirus (HPV) infection in tumor-free patients undergoing tonsillectomy.
We prospectively enrolled healthy patients who underwent tonsillectomy for tumor-free tonsillar disease. Their tonsillar HPV infections were evaluated using CLART HPV2, and subsequent p16 immunohistochemistry was performed in patients with positive HPV infection. Moreover, the results of tonsillar HPV infection were analyzed according to sex, age, and indication of tonsillectomy.
A total of 362 patients were included. HPV test was positive in 8 patients, with an overall prevalence of 2.2%. All detected HPV types were high-risk, including HPV 16 in six patients, HPV 52 in one patient, and HPV 58 in one patient. P16 was negative in all 8 patients with HPV infection. The prevalence of tonsillar HPV infection in males and females was 2.4% (6/246) and 1.7% (2/116), respectively (P > 0.999), and in pediatric and adult patients, 2.2% (5/228) and 2.2% (3/134), respectively (P > 0.999). The prevalence showed a bimodal peak at 1st and 6th decades, with the prevalence of 2.6% (5/194) and 7.9% (3/38), respectively. The prevalence of tonsillar HPV infection in tonsillitis and non-tonsillitis groups were 0.0% (0/104) and 3.1% (8/258), respectively (P = 0.111).
The prevalence of tonsillar HPV infection in tumor-free patients was low, but all detected HPV infections were high-risk types. Our results support using a 9-valent vaccine which covers all high-risk HPV types found in this study.
本研究评估了接受扁桃体切除术的无肿瘤患者扁桃体人乳头瘤病毒（HPV）感染的患病率及特征。
我们前瞻性纳入了因无肿瘤性扁桃体疾病而接受扁桃体切除术的健康患者。使用CLART HPV2评估其扁桃体HPV感染情况，并对HPV感染阳性患者进行后续的p16免疫组化检测。此外，根据性别、年龄和扁桃体切除指征分析扁桃体HPV感染结果。
共纳入362例患者。8例患者HPV检测呈阳性，总体患病率为2.2%。所有检测到的HPV类型均为高危型，其中6例患者为HPV 16型，1例患者为HPV 52型，1例患者为HPV 58型。8例HPV感染患者的p16均为阴性。男性和女性扁桃体HPV感染患病率分别为2.4%（6/246）和1.7%（2/116）（P>0.999），儿童和成人患者分别为2.2%（5/228）和2.2%（3/134）（P>0.999）。患病率在第1个和第6个十年出现双峰，分别为2.6%（5/194）和7.9%（3/38）。扁桃体炎组和非扁桃体炎组的扁桃体HPV感染患病率分别为0.0%（0/104）和3.1%（8/258）（P=0.111）。
无肿瘤患者扁桃体HPV感染患病率较低，但所有检测到的HPV感染均为高危型。我们的结果支持使用涵盖本研究中发现的所有高危HPV类型的9价疫苗。
